<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chediak-Higashi syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chediak-Higashi syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chediak-Higashi syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kaan Boztug, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Luigi D Notarangelo, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chediak-Higashi syndrome (CHS; MIM #214500) is a rare, autosomal recessive disorder characterized by recurrent bacterial infections including pyogenic infections, oculocutaneous albinism that is present to a variable extent, progressive neurologic abnormalities, mild coagulation defects, and a high risk of developing hemophagocytic lymphohistiocytosis (HLH; formerly termed the "accelerated phase" of the disease) [<a href="#rid1">1-5</a>].</p><p>The diagnosis of CHS is suggested by pathognomonic giant cytoplasmic granules in leukocytes and platelets on a peripheral smear and is confirmed by identification of a pathogenic variant in the <em>CHS1/</em>lysosomal trafficking regulator (<em>LYST</em>) gene. Allogeneic hematopoietic cell transplantation (HCT) is the treatment of choice.</p><p>This topic reviews the pathogenesis, clinical manifestations, diagnosis, treatment, and prognosis of CHS. An overview of primary disorders of phagocytic function is presented separately. (See  <a class="medical medical_review" href="/d/html/3913.html" rel="external">"Primary disorders of phagocyte number and/or function: An overview"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>CHS is a rare disorder, with an estimated incidence of &lt;1 in 1,000,000. Less than 500 cases have been reported worldwide [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H1395702114"><span class="h1">GENETICS</span><span class="headingEndMark"> — </span>The gene responsible for CHS is called Beige in mice because it was first discovered in a mouse model with an altered "beige" coat color [<a href="#rid6">6-9</a>]. This mouse model has been an important source of information on the disease. The mouse gene and the defective human gene, called lysosomal trafficking regulator (<em>CHS1</em>/<em>LYST</em>), are part of the Beige and Chediak-Higashi (BEACH) family of vesicle trafficking regulatory proteins. Studies have also modeled CHS in <em>Drosophila</em> showing that the <em>Drosophila</em> Mauve, a counterpart of <em>LYST</em>, suppresses vesicle fusion events with lipid droplets [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The underlying defect in CHS is abnormal organellar protein trafficking that leads to aberrant fusion of vesicles and failure to transport lysosomes to the appropriate site of action [<a href="#rid7">7</a>]. This defect is due to a mutation in the <em>CHS1</em>/<em>LYST</em> gene at 1q42.1-2 (MIM #214500) [<a href="#rid8">8,9</a>]. Most reported mutations are nonsense or null mutations, resulting in an absent CHS1/LYST protein [<a href="#rid1">1</a>]. A genotype-phenotype relationship appears to exist, with milder forms of CHS associated with missense mutations that probably encode a protein with residual function [<a href="#rid1">1</a>].</p><p>The CHS1/LYST protein is widely expressed in the cytosol [<a href="#rid7">7</a>]. CHS is critical for regulating size and trafficking of lysosomes by membrane fusion and fission. Studies have also suggested that the biochemical defect in CHS is due to decreased levels of protein kinase C [<a href="#rid11">11</a>]. Aberrant cortical actin density and granule size are (at least partially) causative for the cytotoxic defect by inhibiting lytic granule release [<a href="#rid12">12</a>]. A study modeled the giant granule formation in myeloid cells, the characteristic cellular defects of CHS, using patient-derived induced pluripotent stem cells (iPSCs) [<a href="#rid13">13</a>].</p><p>Altered lysosomes/granules are found in all cell types in CHS and are the hallmark of the disease  (<a class="graphic graphic_picture graphicRef57556" href="/d/graphic/57556.html" rel="external">picture 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Melanocytes contain enlarged pigment granules (melanosomes) that are not appropriately transferred to keratinocytes or epithelial cells, resulting in a variable degree of oculocutaneous albinism [<a href="#rid14">14,15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neutrophils have giant azurophilic granules [<a href="#rid16">16</a>], and cytotoxic T cells have enlarged mature secretory cytolytic granules [<a href="#rid17">17,18</a>]. These abnormal granules do not appropriately release their contents in the setting of bacterial or viral infections, leading to impaired bactericidal and cytotoxic function. Neutrophils also have impaired chemotaxis [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The number of platelet-dense bodies (serotonin-storage granules) is significantly reduced, resulting in a platelet storage pool deficiency and bleeding diathesis [<a href="#rid20">20,21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Plasma membrane repair, which is a lysosome-mediated process, is also impaired [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Data in mice show that the accumulation of phagolysosomes in pigment epithelium of the retina and the induction of oxidative stress cause a reduction of retinal adhesion, potentially explaining some of the ocular disease manifestations [<a href="#rid23">23</a>].</p><p></p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Patients are typically identified in infancy or early childhood when they present with partial oculocutaneous albinism type 2 (OCA2) and recurrent pyogenic infections [<a href="#rid6">6</a>]. Less commonly, patients may present with hemophagocytic lymphohistiocytosis (HLH; formerly termed the "accelerated phase" of CHS).</p><p class="headingAnchor" id="H961387502"><span class="h2">Aberrant pigmentation and ocular manifestations</span><span class="headingEndMark"> — </span>The degree of hypopigmentation varies, but most patients have fair skin and sparse light-blond, gray, or white hair that often has a metallic sheen  (<a class="graphic graphic_picture graphicRef75571" href="/d/graphic/75571.html" rel="external">picture 2</a>) [<a href="#rid24">24</a>]. Speckled hyperpigmentation and hypopigmentation of sun-exposed areas may be seen in patients with more darkly pigmented skin tones [<a href="#rid25">25</a>]. Pigmentation of the irides and retinae is also reduced [<a href="#rid26">26</a>]. Patients have light-colored, usually blue, eyes. Ocular manifestations include photophobia, decreased visual acuity, nystagmus, and strabismus.</p><p class="headingAnchor" id="H1034460080"><span class="h2">Immunodeficiency with predominantly bacterial infections</span><span class="headingEndMark"> — </span>Pyogenic infections are frequent, severe, and related to the neutrophil dysfunction characteristic of CHS (see <a class="local">'Pathogenesis'</a> above). The most common sites of infection are the skin, respiratory tract, and mucous membranes. Cutaneous infections range from superficial pyoderma to deep abscesses and ulcerations [<a href="#rid27">27</a>]. The deeper lesions heal slowly and leave atrophic scars. The most common causative organism is <em>Staphylococcus aureus</em>. <em>Streptococcus pyogenes</em> and <em>Pneumococcus</em> species are other common infectious organisms in CHS.</p><p class="headingAnchor" id="H585047221"><span class="h2">Coagulation defects</span><span class="headingEndMark"> — </span>Patients have a mild coagulation defect that results in easy bruising and abnormal bleeding, especially of mucosal tissue [<a href="#rid20">20,21</a>]. Bleeding may become more severe in patients who have developed HLH. Hepatosplenomegaly and lymphadenopathy are common and become more pronounced with HLH. (See <a class="local">'Hemophagocytic lymphohistiocytosis/accelerated phase'</a> below.)</p><p class="headingAnchor" id="H2633662017"><span class="h2">Other disease manifestations</span><span class="headingEndMark"> — </span>Gingivitis, oral ulcerations, and periodontal disease are common [<a href="#rid28">28-30</a>]. Defective Toll-like receptor (TLR) expression and function, in particular TLR2/4, may underlie immune dysregulation and influence periodontal disease [<a href="#rid31">31</a>]. Enterocolitis has also been reported [<a href="#rid32">32</a>]. Renal function impairment is reported in animals with the disease [<a href="#rid33">33</a>], and renal giant cytoplasmic inclusion has been reported in ultrastructural studies of human patients [<a href="#rid34">34</a>], although impaired renal function is not a characteristic feature in CHS patients.</p><p class="headingAnchor" id="H3014870754"><span class="h2">Progressive neurologic dysfunction</span><span class="headingEndMark"> — </span>Approximately 10 to 15 percent of patients who survive early childhood with curative hematopoietic cell transplantation (HCT), despite serious infections, develop severe, debilitating neurologic manifestations in adolescence and early adulthood [<a href="#rid35">35-39</a>]. Both the peripheral and central nervous systems are involved. Neurologic defects include weakness and sensory deficits due to peripheral neuropathy, ataxia, tremors, cranial nerve palsies, progressive intellectual decline, and seizures. Spinocerebellar degeneration, Parkinson disease-like movement disorders, and dementia also occur, especially in the second and third decades of life [<a href="#rid40">40</a>]. HCT does not prevent this neurologic deterioration.</p><p class="headingAnchor" id="H5"><span class="h2">Hemophagocytic lymphohistiocytosis/accelerated phase</span><span class="headingEndMark"> — </span>Patients who do not die from infection eventually enter the "accelerated phase" of the disease, characterized by HLH disease with massive lymphohistiocytic infiltration of virtually all organ systems and even more profound immunodeficiency, typically occurring in infancy or the first decade of life [<a href="#rid41">41,42</a>]. (See  <a class="medical medical_review" href="/d/html/87499.html" rel="external">"Clinical features and diagnosis of hemophagocytic lymphohistiocytosis", section on 'Clinical features'</a>.)</p><p>Patients with HLH present with fever, increased hepatosplenomegaly and lymphadenopathy, and worsened pancytopenia and bleeding. This phase occurs in more than 80 percent of patients and is usually lethal. As with other genetically determined forms of HLH (primary/familial HLH), onset of disease is typically triggered by viral infections, particularly the Epstein-Barr virus [<a href="#rid7">7,43,44</a>]. The characteristic lack of natural killer (NK) cell function in CHS, but also abnormal surface expression of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) [<a href="#rid45">45</a>] and reduced cytotoxic T lymphocyte (CTL) and NK cell cytotoxicity [<a href="#rid42">42</a>], predispose to development of HLH with viral infections.</p><p class="headingAnchor" id="H6"><span class="h1">LABORATORY AND IMAGING FINDINGS</span><span class="headingEndMark"> — </span>Neutropenia is a common laboratory finding and is probably due to intramedullary destruction of neutrophils [<a href="#rid46">46</a>]. Neutrophils and monocytes have decreased chemotactic responses [<a href="#rid19">19</a>]. Intracellular killing of bacteria is also impaired [<a href="#rid47">47</a>]. Natural killer (NK) cells are present, but NK cytotoxicity is nearly absent [<a href="#rid48">48</a>]. Antibody-dependent cellular cytotoxicity is also decreased [<a href="#rid17">17</a>]. B cell function is usually normal [<a href="#rid49">49</a>]. Hypergammaglobulinemia is often seen secondary to frequent infections [<a href="#rid50">50</a>].</p><p>Patients with CHS have abnormal platelet aggregation and bleeding time [<a href="#rid20">20,21</a>]. Thrombocytopenia is common in patients with hemophagocytic lymphohistiocytosis (HLH).</p><p>Diffuse atrophy of the brain and spinal cord is noted on computed tomography (CT) scan and magnetic resonance imaging (MRI) [<a href="#rid51">51</a>]. There is also markedly delayed nerve conduction time on electromyography (EMG). An electroencephalography (EEG) may reveal seizure activity.</p><p>Giant granules are seen in Schwann cells and muscle cells [<a href="#rid36">36,52</a>]. Examination of skin melanocytes reveals giant melanosomes [<a href="#rid14">14</a>]. Light microscopy of hair shafts shows small aggregates of clumped pigmentation that are regularly distributed  (<a class="graphic graphic_picture graphicRef128394" href="/d/graphic/128394.html" rel="external">picture 3</a>) [<a href="#rid53">53</a>]. Shafts appear bright and polychromatic under polarized light microscopy.</p><p class="headingAnchor" id="H7"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of CHS is typically suspected in patients with partial oculocutaneous albinism and recurrent pyogenic infections and is made by examining a peripheral blood smear for the classic giant azurophilic granules in neutrophils, eosinophils, and other granulocytes  (<a class="graphic graphic_picture graphicRef57556" href="/d/graphic/57556.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef71313" href="/d/graphic/71313.html" rel="external">picture 4</a>). These large granules are found in all granule-containing cells, including peripheral blood and bone marrow cells, melanocytes, peripheral and central nerve tissue, renal tubular epithelium, fibroblasts, and gastric mucosa [<a href="#rid54">54,55</a>].</p><p>Definitive diagnosis is based upon genetic testing for mutations in the <em>CHS1</em>/<em>LYST</em> gene. The gene is large, and most mutations are unique. Thus, identifying the exact mutation and differentiating true disease-causing mutations from benign genetic variants can be a challenge.</p><p>The diagnostic criteria for CHS in patients who present with hemophagocytic lymphohistiocytosis (HLH) are the same as for HLH due to other primary genetic defects and include five out of the following eight criteria: fever; splenomegaly; cytopenia in at least two lineages in peripheral blood; hypertriglyceridemia and/or hypofibrinogenemia; hemophagocytosis in bone marrow, spleen, or lymph nodes; low or absent natural killer (NK) cell activity; hyperferritinemia; and high levels of soluble interleukin (IL) 2 receptor [<a href="#rid56">56</a>]. The diagnosis of HLH is reviewed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/87499.html" rel="external">"Clinical features and diagnosis of hemophagocytic lymphohistiocytosis", section on 'Diagnosis'</a>.)</p><p>As for other genetic diseases, prenatal diagnosis is possible and is commonly performed by capillary sequencing of the <em>CHS1/LYST</em> gene.</p><p class="headingAnchor" id="H8"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>There are several other rare disorders combining both partial albinism and immunodeficiency that are in the differential diagnosis. These include Griscelli syndrome and Hermansky-Pudlak syndromes (HPS). Several features including neurologic symptoms prior to hemophagocytic lymphohistiocytosis (HLH) onset (particularly peripheral neuropathy) and giant intracellular granules in leukocytes are characteristic of CHS but are not seen in these other conditions.<strong> </strong>However, genetic testing is strongly recommended to differentiate these rare disorders since they have partial phenotypic overlap and treatment is not identical.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Griscelli syndrome</strong> – Griscelli syndrome is a rare, autosomal recessive disorder characterized by partial oculocutaneous albinism and immunodeficiency [<a href="#rid57">57</a>]. This disorder is due to a mutation in one of three intracellular trafficking genes. Griscelli syndrome may also be distinguished from CHS by examination of hair shafts [<a href="#rid53">53</a>]. Larger, irregular clumps of melanin granules are distributed mainly near the medulla of the hair shaft. The shaft appears uniformly white under polarized light microscopy. (See  <a class="medical medical_review" href="/d/html/3951.html" rel="external">"Syndromic immunodeficiencies", section on 'Griscelli syndrome'</a> and <a class="local">'Laboratory and imaging findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hermansky-Pudlak syndromes</strong> – HPS denote a group of rare, autosomal recessive disorders characterized by partial oculocutaneous albinism and a platelet storage pool deficiency [<a href="#rid58">58</a>]. Mutations in 10 different genes are associated with HPS. These mutations lead to defects in cytoplasmic organelles involved in protein sorting and trafficking. Three of these types of HPS also have an associated immunodeficiency. These include HPS-2 caused by an autosomal recessive mutation in the adaptor-related protein complex 3 beta 1 subunit (<em>AP3B1</em>) gene [<a href="#rid59">59-63</a>], HPS-9 caused by an autosomal recessive mutation in the biogenesis of lysosomal organelles complex 1 subunit 6 (<em>BLOC1S6</em>) gene [<a href="#rid64">64</a>], and HPS-10 caused by an autosomal-recessive mutation in the adaptor-related protein complex 3 delta 1 subunit (<em>AP3D1</em>) gene [<a href="#rid65">65</a>]. Other types of HPS have associated pulmonary fibrosis and colitis [<a href="#rid66">66,67</a>]. (See  <a class="medical medical_review" href="/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)", section on 'Hermansky-Pudlak syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other conditions combining partial albinism and immunodeficiency</strong> – Another condition in the differential diagnosis is deficiency of the endosomal adaptor protein (mitogen-activated protein binding protein interacting protein [MAPBPIP]) encoded by the late endosomal/lysosomal adaptor, MAPK and mTOR activator 2 (<em>LAMTOR2</em>) gene [<a href="#rid68">68</a>]. Features in this disorder not seen in CHS include short stature and coarse facial features.</p><p></p><p>The differential diagnosis in patients who present with HLH (accelerated phase) includes a number of common conditions that cause fever, pancytopenia, hepatic abnormalities, or neurologic findings. Cytopenias, a very high ferritin level, and liver function abnormalities are helpful in distinguishing HLH from these other conditions. The differential diagnosis of HLH is reviewed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/87499.html" rel="external">"Clinical features and diagnosis of hemophagocytic lymphohistiocytosis", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The initial treatment of CHS includes prophylactic antibiotics and aggressive therapy for acute bacterial infections (see  <a class="medical medical_review" href="/d/html/3948.html" rel="external">"Inborn errors of immunity (primary immunodeficiencies): Overview of management"</a>). Other pretransplant therapies include granulocyte colony stimulating factor (G-CSF) to correct neutropenia and decrease infection [<a href="#rid69">69</a>] and interferon gamma, which may partially restore function of natural killer (NK) cells. Allogeneic hematopoietic cell transplantation (HCT), including cord blood transplant, is the treatment of choice to correct the immunologic and hematologic manifestations of CHS, although it does not prevent the progressive neurologic deterioration or the oculocutaneous albinism [<a href="#rid51">51,70,71</a>].</p><p>A deficiency or deterioration of cytotoxic T cell function may predispose to hemophagocytic lymphohistiocytosis (HLH) and is of use in determining the need for early HCT [<a href="#rid42">42</a>]. HLH treatment in patients with CHS follows the same clinical protocols for familial/primary HLH, such as the HLH2004 protocol. Although systematic data are lacking, it is assumed that the outcome of HCT depends upon prior infections and whether HLH has developed in an individual patient. Thus, early, preemptive HCT is preferred, in particular when a matched sibling or unrelated donor is available. Successful HCT with donor immune reconstitution will normalize the risk of infection-triggered HLH. (See  <a class="medical medical_review" href="/d/html/8384.html" rel="external">"Treatment and prognosis of hemophagocytic lymphohistiocytosis"</a>.)</p><p>Transplantation appears to be most successful if a human leukocyte antigen (HLA) identical donor is used and if the transplantation is performed prior to the onset of HLH or during remission. However, even patients with HLH may benefit from transplantation [<a href="#rid72">72</a>]. Successfully transplanted patients have improved NK cell function, no significant infections, and do not progress to or have a recurrence of HLH. In a 2013 report from Japan, five of six patients with CHS survived transplantation [<a href="#rid73">73</a>]. HCT was performed prior to the development of HLH in all six patients. Three additional children with CHS successfully underwent HCT with umbilical cord blood [<a href="#rid74">74</a>]. (See  <a class="medical medical_review" href="/d/html/3941.html" rel="external">"Hematopoietic cell transplantation for non-SCID inborn errors of immunity"</a>.)</p><p>High-dose glucocorticoids and splenectomy have been used with some success to induce a transient remission in the accelerated phase/HLH [<a href="#rid75">75</a>]. Intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a>, antivirals (eg, <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>), and chemotherapy (eg, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>) have also been used to induce transient remission of HLH [<a href="#rid76">76</a>]. However, treatment with these agents is not curative, and HLH usually recurs in a more aggressive and difficult-to-manage form.</p><p>Given the skin hypopigmentation, patients with CHS should avoid significant levels of ultraviolet (UV) irradiation (eg, sunlight exposure) and wear sunscreen for protection.</p><p class="headingAnchor" id="H10"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Most patients with CHS die from pyogenic infection before seven years of age if not transplanted. Hemorrhage is a less common cause of death. The five-year probability of survival posttransplantation was 62 percent in a review of 35 children with CHS [<a href="#rid70">70</a>]. However, most transplanted patients and those few patients who survive childhood without transplantation develop neurologic deficits by the time they reach their early 20s [<a href="#rid51">51</a>]. These deficits include cerebellar ataxia, with difficulty walking and loss of balance, tremor, peripheral neuropathy, and low cognitive abilities. These neurologic sequelae can be quite debilitating. (See <a class="local">'Progressive neurologic dysfunction'</a> above.)</p><p class="headingAnchor" id="H1481194276"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112831.html" rel="external">"Society guideline links: Inborn errors of immunity (previously called primary immunodeficiencies)"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Chediak-Higashi syndrome (CHS) is a rare, autosomal recessive disorder characterized by recurrent pyogenic infections, partial oculocutaneous albinism, progressive neurologic abnormalities, mild coagulation defects, and hemophagocytic histiocytosis (HLH; formerly termed the "accelerated phase" of the disease). (See <a class="local">'Introduction'</a> above and <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics and pathogenesis</strong> – The defective gene, called lysosomal trafficking regulator (<em>CHS1</em>/<em>LYST</em>), is part of the BEACH family of vesicle trafficking regulatory proteins. (See <a class="local">'Genetics'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis is made by examination of a peripheral smear for pathognomonic giant cytoplasmic granules in leukocytes and platelets and molecular analysis of the <em>CHS1/LYST</em> gene. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcome</strong> – Patients who do not die from infection eventually develop HLH, characterized by massive lymphohistiocytic infiltration of virtually all organ systems. (See <a class="local">'Hemophagocytic lymphohistiocytosis/accelerated phase'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematopoietic cell transplantation</strong> – Hematopoietic cell transplantation (HCT) is the treatment of choice to correct the immunologic and hematologic manifestations of CHS. Treatment with HCT prevents infections and development of HLH, but patients still develop neurologic deficits, and the oculocutaneous albinism is not corrected. (See <a class="local">'Treatment'</a> above and <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H865637202"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge Robert L Roberts, MD, PhD and Kevin Yeh-Sheng Wang, MD, LAc, who contributed as authors to earlier versions of this topic review.</p><p>The editorial staff at UpToDate also acknowledge E Richard Stiehm, MD, who contributed as a Section Editor to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Karim MA, Suzuki K, Fukai K, et al. Apparent genotype-phenotype correlation in childhood, adolescent, and adult Chediak-Higashi syndrome. Am J Med Genet 2002; 108:16.</a></li><li><a class="nounderline abstract_t">Beguez-Cesar AB. Neutropenia cronica maligna familiar con granulaciones atipicas de los leucocitos. Bol Soc Cuba Pediatr 1943; 15:900.</a></li><li><a class="nounderline abstract_t">CHEDIAK MM. [New leukocyte anomaly of constitutional and familial character]. Rev Hematol 1952; 7:362.</a></li><li><a class="nounderline abstract_t">HIGASHI O. Congenital gigantism of peroxidase granules; the first case ever reported of qualitative abnormity of peroxidase. Tohoku J Exp Med 1954; 59:315.</a></li><li><a class="nounderline abstract_t">SATO A. Chédiak and Higashi's disease: probable identity of a new leucocytal anomaly (Chédiak) and congenital gigantism of peroxidase granules (Higashi). Tohoku J Exp Med 1955; 61:201.</a></li><li><a class="nounderline abstract_t">Kaplan J, De Domenico I, Ward DM. Chediak-Higashi syndrome. Curr Opin Hematol 2008; 15:22.</a></li><li><a class="nounderline abstract_t">Perou CM, Leslie JD, Green W, et al. The Beige/Chediak-Higashi syndrome gene encodes a widely expressed cytosolic protein. J Biol Chem 1997; 272:29790.</a></li><li><a class="nounderline abstract_t">Barbosa MD, Nguyen QA, Tchernev VT, et al. Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature 1996; 382:262.</a></li><li><a class="nounderline abstract_t">Nagle DL, Karim MA, Woolf EA, et al. Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. Nat Genet 1996; 14:307.</a></li><li><a class="nounderline abstract_t">Lattao R, Rangone H, Llamazares S, Glover DM. Mauve/LYST limits fusion of lysosome-related organelles and promotes centrosomal recruitment of microtubule nucleating proteins. Dev Cell 2021; 56:1000.</a></li><li><a class="nounderline abstract_t">Ito M, Tanabe F, Takami Y, et al. Rapid down-regulation of protein kinase C in (Chediak-Higashi syndrome) beige mouse by phorbol ester. Biochem Biophys Res Commun 1988; 153:648.</a></li><li><a class="nounderline abstract_t">Gil-Krzewska A, Saeed MB, Oszmiana A, et al. An actin cytoskeletal barrier inhibits lytic granule release from natural killer cells in patients with Chediak-Higashi syndrome. J Allergy Clin Immunol 2018; 142:914.</a></li><li><a class="nounderline abstract_t">Oh S, Niwa A, Nagahashi A, et al. iPS cells from Chediak-Higashi syndrome patients recapitulate the giant granules in myeloid cells. Pediatr Int 2022; 64:e15390.</a></li><li><a class="nounderline abstract_t">Zelickson AS, Windhorst DB, White JG, Good RA. The Chediak-Higashi syndrome: formation of giant melanosomes and the basis of hypopigmentation. J Invest Dermatol 1967; 49:575.</a></li><li><a class="nounderline abstract_t">Zhao H, Boissy YL, Abdel-Malek Z, et al. On the analysis of the pathophysiology of Chediak-Higashi syndrome. Defects expressed by cultured melanocytes. Lab Invest 1994; 71:25.</a></li><li><a class="nounderline abstract_t">Kjeldsen L, Calafat J, Borregaard N. Giant granules of neutrophils in Chediak-Higashi syndrome are derived from azurophil granules but not from specific and gelatinase granules. J Leukoc Biol 1998; 64:72.</a></li><li><a class="nounderline abstract_t">Baetz K, Isaaz S, Griffiths GM. Loss of cytotoxic T lymphocyte function in Chediak-Higashi syndrome arises from a secretory defect that prevents lytic granule exocytosis. J Immunol 1995; 154:6122.</a></li><li><a class="nounderline abstract_t">Stinchcombe JC, Page LJ, Griffiths GM. Secretory lysosome biogenesis in cytotoxic T lymphocytes from normal and Chediak Higashi syndrome patients. Traffic 2000; 1:435.</a></li><li><a class="nounderline abstract_t">Clark RA, Kimball HR. Defective granulocyte chemotaxis in the Chediak-Higashi syndrome. J Clin Invest 1971; 50:2645.</a></li><li><a class="nounderline abstract_t">Buchanan GR, Handin RI. Platelet function in the Chediak-Higashi syndrome. Blood 1976; 47:941.</a></li><li><a class="nounderline abstract_t">Rendu F, Breton-Gorius J, Lebret M, et al. Evidence that abnormal platelet functions in human Chédiak-Higashi syndrome are the result of a lack of dense bodies. Am J Pathol 1983; 111:307.</a></li><li><a class="nounderline abstract_t">Huynh C, Roth D, Ward DM, et al. Defective lysosomal exocytosis and plasma membrane repair in Chediak-Higashi/beige cells. Proc Natl Acad Sci U S A 2004; 101:16795.</a></li><li><a class="nounderline abstract_t">Ji X, Zhao L, Umapathy A, et al. Deficiency in Lyst function leads to accumulation of secreted proteases and reduced retinal adhesion. PLoS One 2022; 17:e0254469.</a></li><li><a class="nounderline abstract_t">Barak Y, Nir E. Chediak-Higashi syndrome. Am J Pediatr Hematol Oncol 1987; 9:42.</a></li><li><a class="nounderline abstract_t">Al-Khenaizan S. Hyperpigmentation in Chediak-Higashi syndrome. J Am Acad Dermatol 2003; 49:S244.</a></li><li><a class="nounderline abstract_t">Creel D, Boxer LA, Fauci AS. Visual and auditory anomalies in Chediak-Higashi syndrome. Electroencephalogr Clin Neurophysiol 1983; 55:252.</a></li><li><a class="nounderline abstract_t">Weary PE, Bender AS. Chediak-Higashi syndrome with severe cutaneous involvement. Occurrence in two brothers 14 and 15 years of age. Arch Intern Med 1967; 119:381.</a></li><li><a class="nounderline abstract_t">Delcourt-Debruyne EM, Boutigny HR, Hildebrand HF. Features of severe periodontal disease in a teenager with Chédiak-Higashi syndrome. J Periodontol 2000; 71:816.</a></li><li><a class="nounderline abstract_t">Bailleul-Forestier I, Monod-Broca J, Benkerrou M, et al. Generalized periodontitis associated with Chédiak-Higashi syndrome. J Periodontol 2008; 79:1263.</a></li><li><a class="nounderline abstract_t">de Arruda JAA, Sousa-Neto SS, Abreu LG, et al. Oral manifestations of Chediak-Higashi syndrome: A systematic review. Dis Mon 2023; 69:101356.</a></li><li><a class="nounderline abstract_t">Thumbigere Math V, Rebouças P, Giovani PA, et al. Periodontitis in Chédiak-Higashi Syndrome: An Altered Immunoinflammatory Response. JDR Clin Trans Res 2018; 3:35.</a></li><li><a class="nounderline abstract_t">Ishii E, Matui T, Iida M, et al. Chediak-Higashi syndrome with intestinal complication. Report of a case. J Clin Gastroenterol 1987; 9:556.</a></li><li><a class="nounderline abstract_t">Hargis AM, Prieur DJ. Animal model: renal lesions in cats with Chediak-Higashi-Steinbrinck syndrome. Am J Med Genet 1987; 26:169.</a></li><li><a class="nounderline abstract_t">de Chadarévian JP. Renal giant cytoplasmic inclusions in Chédiak-Higashi syndrome: first ultrastructural demonstration in a human biopsy. Ultrastruct Pathol 2011; 35:172.</a></li><li><a class="nounderline abstract_t">Sung JH, Stadlan EM. Neuropathological changes in Chediak-Higashi disease. J Neuropathol Exp Neurol 1968; 27:156.</a></li><li><a class="nounderline abstract_t">Sung JH, Meyers JP, Stadlan EM, et al. Neuropathological changes in Chédiak-Higashi disease. J Neuropathol Exp Neurol 1969; 28:86.</a></li><li><a class="nounderline abstract_t">Misra VP, King RH, Harding AE, et al. Peripheral neuropathy in the Chediak-Higashi syndrome. Acta Neuropathol 1991; 81:354.</a></li><li><a class="nounderline abstract_t">Uyama E, Hirano T, Ito K, et al. Adult Chédiak-Higashi syndrome presenting as parkinsonism and dementia. Acta Neurol Scand 1994; 89:175.</a></li><li><a class="nounderline abstract_t">Mathis S, Cintas P, de Saint-Basile G, et al. Motor neuronopathy in Chediak-Higashi syndrome. J Neurol Sci 2014; 344:203.</a></li><li><a class="nounderline abstract_t">Lozano ML, Rivera J, Sánchez-Guiu I, Vicente V. Towards the targeted management of Chediak-Higashi syndrome. Orphanet J Rare Dis 2014; 9:132.</a></li><li class="breakAll">Rosenzweig SD, Uzel G, Holland S. Phagocytic disorders. In: Immunologic disorders in infants and children, 5th ed, Stiehm ER, Ochs HD, Winkelstein JA (Eds), Elsevier Saunders, Philadelphia 2004. p.618.</li><li><a class="nounderline abstract_t">Jessen B, Maul-Pavicic A, Ufheil H, et al. Subtle differences in CTL cytotoxicity determine susceptibility to hemophagocytic lymphohistiocytosis in mice and humans with Chediak-Higashi syndrome. Blood 2011; 118:4620.</a></li><li><a class="nounderline abstract_t">Rubin CM, Burke BA, McKenna RW, et al. The accelerated phase of Chediak-Higashi syndrome. An expression of the virus-associated hemophagocytic syndrome? Cancer 1985; 56:524.</a></li><li><a class="nounderline abstract_t">Merino F, Henle W, Ramírez-Duque P. Chronic active Epstein-Barr virus infection in patients with Chediak-Higashi syndrome. J Clin Immunol 1986; 6:299.</a></li><li><a class="nounderline abstract_t">Barrat FJ, Le Deist F, Benkerrou M, et al. Defective CTLA-4 cycling pathway in Chediak-Higashi syndrome: a possible mechanism for deregulation of T lymphocyte activation. Proc Natl Acad Sci U S A 1999; 96:8645.</a></li><li><a class="nounderline abstract_t">Blume RS, Bennett JM, Yankee RA, Wolff SM. Defective granulocyte regulation in the Chediak-Higashi syndrome. N Engl J Med 1968; 279:1009.</a></li><li><a class="nounderline abstract_t">Root RK, Rosenthal AS, Balestra DJ. Abnormal bactericidal, metabolic, and lysosomal functions of Chediak-Higashi Syndrome leukocytes. J Clin Invest 1972; 51:649.</a></li><li><a class="nounderline abstract_t">Brahmi Z. Nature of natural killer cell hyporesponsiveness in the Chediak-Higashi syndrome. Hum Immunol 1983; 6:45.</a></li><li><a class="nounderline abstract_t">Klein M, Roder J, Haliotis T, et al. Chédiak-Higashi gene in humans. II. The selectivity of the defect in natural-killer and antibody-dependent cell-mediated cytotoxicity function. J Exp Med 1980; 151:1049.</a></li><li><a class="nounderline abstract_t">Introne W, Boissy RE, Gahl WA. Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome. Mol Genet Metab 1999; 68:283.</a></li><li><a class="nounderline abstract_t">Tardieu M, Lacroix C, Neven B, et al. Progressive neurologic dysfunctions 20 years after allogeneic bone marrow transplantation for Chediak-Higashi syndrome. Blood 2005; 106:40.</a></li><li><a class="nounderline abstract_t">Pettit RE, Berdal KG. Chédiak-Higashi syndrome. Neurologic appearance. Arch Neurol 1984; 41:1001.</a></li><li><a class="nounderline abstract_t">Valente NY, Machado MC, Boggio P, et al. Polarized light microscopy of hair shafts aids in the differential diagnosis of Chédiak-Higashi and Griscelli-Prunieras syndromes. Clinics (Sao Paulo) 2006; 61:327.</a></li><li><a class="nounderline abstract_t">Burkhardt JK, Wiebel FA, Hester S, Argon Y. The giant organelles in beige and Chediak-Higashi fibroblasts are derived from late endosomes and mature lysosomes. J Exp Med 1993; 178:1845.</a></li><li><a class="nounderline abstract_t">Ostlund RE Jr, Tucker RW, Leung JT, et al. The cytoskeleton in Chediak-Higashi syndrome fibroblasts. Blood 1980; 56:806.</a></li><li><a class="nounderline abstract_t">Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48:124.</a></li><li><a class="nounderline abstract_t">de Saint Basile. Chediak-Higashi and Griscelli syndromes. Immunol Allergy Clin North Am 2002; 22:301.</a></li><li><a class="nounderline abstract_t">Di Pietro SM, Dell'Angelica EC. The cell biology of Hermansky-Pudlak syndrome: recent advances. Traffic 2005; 6:525.</a></li><li><a class="nounderline abstract_t">Dell'Angelica EC, Shotelersuk V, Aguilar RC, et al. Altered trafficking of lysosomal proteins in Hermansky-Pudlak syndrome due to mutations in the beta 3A subunit of the AP-3 adaptor. Mol Cell 1999; 3:11.</a></li><li><a class="nounderline abstract_t">Enders A, Zieger B, Schwarz K, et al. Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II. Blood 2006; 108:81.</a></li><li><a class="nounderline abstract_t">Fontana S, Parolini S, Vermi W, et al. Innate immunity defects in Hermansky-Pudlak type 2 syndrome. Blood 2006; 107:4857.</a></li><li><a class="nounderline abstract_t">Huizing M, Scher CD, Strovel E, et al. Nonsense mutations in ADTB3A cause complete deficiency of the beta3A subunit of adaptor complex-3 and severe Hermansky-Pudlak syndrome type 2. Pediatr Res 2002; 51:150.</a></li><li><a class="nounderline abstract_t">Jung J, Bohn G, Allroth A, et al. Identification of a homozygous deletion in the AP3B1 gene causing Hermansky-Pudlak syndrome, type 2. Blood 2006; 108:362.</a></li><li><a class="nounderline abstract_t">Badolato R, Prandini A, Caracciolo S, et al. Exome sequencing reveals a pallidin mutation in a Hermansky-Pudlak-like primary immunodeficiency syndrome. Blood 2012; 119:3185.</a></li><li><a class="nounderline abstract_t">Ammann S, Schulz A, Krägeloh-Mann I, et al. Mutations in AP3D1 associated with immunodeficiency and seizures define a new type of Hermansky-Pudlak syndrome. Blood 2016; 127:997.</a></li><li><a class="nounderline abstract_t">Pierson DM, Ionescu D, Qing G, et al. Pulmonary fibrosis in hermansky-pudlak syndrome. a case report and review. Respiration 2006; 73:382.</a></li><li><a class="nounderline abstract_t">Tager AM, Sharma A, Mark EJ. Case records of the Massachusetts General Hospital. Case 32-2009. A 27-year-old man with progressive dyspnea. N Engl J Med 2009; 361:1585.</a></li><li><a class="nounderline abstract_t">Bohn G, Allroth A, Brandes G, et al. A novel human primary immunodeficiency syndrome caused by deficiency of the endosomal adaptor protein p14. Nat Med 2007; 13:38.</a></li><li><a class="nounderline abstract_t">Baldus M, Zunftmeister V, Geibel-Werle G, et al. Chédiak-Higashi-Steinbrinck syndrome (CHS) in a 27-year-old woman--effects of G-CSF treatment. Ann Hematol 1999; 78:321.</a></li><li><a class="nounderline abstract_t">Eapen M, DeLaat CA, Baker KS, et al. Hematopoietic cell transplantation for Chediak-Higashi syndrome. Bone Marrow Transplant 2007; 39:411.</a></li><li><a class="nounderline abstract_t">Haddad E, Le Deist F, Blanche S, et al. Treatment of Chediak-Higashi syndrome by allogenic bone marrow transplantation: report of 10 cases. Blood 1995; 85:3328.</a></li><li><a class="nounderline abstract_t">Sparber-Sauer M, Hönig M, Schulz AS, et al. Patients with early relapse of primary hemophagocytic syndromes or with persistent CNS involvement may benefit from immediate hematopoietic stem cell transplantation. Bone Marrow Transplant 2009; 44:333.</a></li><li><a class="nounderline abstract_t">Nagai K, Ochi F, Terui K, et al. Clinical characteristics and outcomes of chédiak-Higashi syndrome: a nationwide survey of Japan. Pediatr Blood Cancer 2013; 60:1582.</a></li><li><a class="nounderline abstract_t">Thakor A, Geng B, Liebhaber M, et al. Successful stem cell transplantation in Chediak-Higashi syndrome. J Allergy Clin Immunol Pract 2015; 3:271.</a></li><li><a class="nounderline abstract_t">Aslan Y, Erduran E, Gedik Y, et al. The role of high dose methylprednisolone and splenectomy in the accelerated phase of Chédiak-Higashi syndrome. Acta Haematol 1996; 96:105.</a></li><li><a class="nounderline abstract_t">Ayas M, Al-Ghonaium A. In patients with Chediak-Higashi syndrome undergoing allogeneic SCT, does adding etoposide to the conditioning regimen improve the outcome? Bone Marrow Transplant 2007; 40:603.</a></li></ol></div><div id="topicVersionRevision">Topic 3926 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11857544" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Apparent genotype-phenotype correlation in childhood, adolescent, and adult Chediak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Neutropenia cronica maligna familiar con granulaciones atipicas de los leucocitos</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13004553" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : [New leukocyte anomaly of constitutional and familial character].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13169161" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Congenital gigantism of peroxidase granules; the first case ever reported of qualitative abnormity of peroxidase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14396888" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Chédiak and Higashi's disease: probable identity of a new leucocytal anomaly (Chédiak) and congenital gigantism of peroxidase granules (Higashi).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18043242" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Chediak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9368050" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The Beige/Chediak-Higashi syndrome gene encodes a widely expressed cytosolic protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8717042" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Identification of the homologous beige and Chediak-Higashi syndrome genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8896560" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33725482" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Mauve/LYST limits fusion of lysosome-related organelles and promotes centrosomal recruitment of microtubule nucleating proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3382395" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Rapid down-regulation of protein kinase C in (Chediak-Higashi syndrome) beige mouse by phorbol ester.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29241728" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : An actin cytoskeletal barrier inhibits lytic granule release from natural killer cells in patients with Chediak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36259166" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : iPS cells from Chediak-Higashi syndrome patients recapitulate the giant granules in myeloid cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6075990" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The Chediak-Higashi syndrome: formation of giant melanosomes and the basis of hypopigmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8041115" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : On the analysis of the pathophysiology of Chediak-Higashi syndrome. Defects expressed by cultured melanocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9665278" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Giant granules of neutrophils in Chediak-Higashi syndrome are derived from azurophil granules but not from specific and gelatinase granules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7751653" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Loss of cytotoxic T lymphocyte function in Chediak-Higashi syndrome arises from a secretory defect that prevents lytic granule exocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11208129" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Secretory lysosome biogenesis in cytotoxic T lymphocytes from normal and Chediak Higashi syndrome patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4942966" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Defective granulocyte chemotaxis in the Chediak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1276475" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Platelet function in the Chediak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6222656" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Evidence that abnormal platelet functions in human Chédiak-Higashi syndrome are the result of a lack of dense bodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15557559" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Defective lysosomal exocytosis and plasma membrane repair in Chediak-Higashi/beige cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35239671" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Deficiency in Lyst function leads to accumulation of secreted proteases and reduced retinal adhesion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3296821" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Chediak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14576641" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hyperpigmentation in Chediak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6186456" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Visual and auditory anomalies in Chediak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6022522" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Chediak-Higashi syndrome with severe cutaneous involvement. Occurrence in two brothers 14 and 15 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10872965" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Features of severe periodontal disease in a teenager with Chédiak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18597610" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Generalized periodontitis associated with Chédiak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35414415" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Oral manifestations of Chediak-Higashi syndrome: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29276776" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Periodontitis in Chédiak-Higashi Syndrome: An Altered Immunoinflammatory Response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3680907" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Chediak-Higashi syndrome with intestinal complication. Report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3812557" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Animal model: renal lesions in cats with Chediak-Higashi-Steinbrinck syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21657820" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Renal giant cytoplasmic inclusions in Chédiak-Higashi syndrome: first ultrastructural demonstration in a human biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5656570" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Neuropathological changes in Chediak-Higashi disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5766368" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Neuropathological changes in Chédiak-Higashi disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2058369" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Peripheral neuropathy in the Chediak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8030398" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Adult Chédiak-Higashi syndrome presenting as parkinsonism and dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25043664" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Motor neuronopathy in Chediak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25129365" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Towards the targeted management of Chediak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25129365" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Towards the targeted management of Chediak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21878672" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Subtle differences in CTL cytotoxicity determine susceptibility to hemophagocytic lymphohistiocytosis in mice and humans with Chediak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2988747" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The accelerated phase of Chediak-Higashi syndrome. An expression of the virus-associated hemophagocytic syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3018035" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Chronic active Epstein-Barr virus infection in patients with Chediak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10411929" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Defective CTLA-4 cycling pathway in Chediak-Higashi syndrome: a possible mechanism for deregulation of T lymphocyte activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5681251" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Defective granulocyte regulation in the Chediak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4400956" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Abnormal bactericidal, metabolic, and lysosomal functions of Chediak-Higashi Syndrome leukocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6219972" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Nature of natural killer cell hyporesponsiveness in the Chediak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6966316" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Chédiak-Higashi gene in humans. II. The selectivity of the defect in natural-killer and antibody-dependent cell-mediated cytotoxicity function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10527680" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15790783" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Progressive neurologic dysfunctions 20 years after allogeneic bone marrow transplantation for Chediak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6477224" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Chédiak-Higashi syndrome. Neurologic appearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16924324" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Polarized light microscopy of hair shafts aids in the differential diagnosis of Chédiak-Higashi and Griscelli-Prunieras syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7902407" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The giant organelles in beige and Chediak-Higashi fibroblasts are derived from late endosomes and mature lysosomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7426748" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The cytoskeleton in Chediak-Higashi syndrome fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16937360" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Chediak-Higashi and Griscelli syndromes</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15941404" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The cell biology of Hermansky-Pudlak syndrome: recent advances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10024875" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Altered trafficking of lysosomal proteins in Hermansky-Pudlak syndrome due to mutations in the beta 3A subunit of the AP-3 adaptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16551969" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16507770" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Innate immunity defects in Hermansky-Pudlak type 2 syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11809908" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Nonsense mutations in ADTB3A cause complete deficiency of the beta3A subunit of adaptor complex-3 and severe Hermansky-Pudlak syndrome type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16537806" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Identification of a homozygous deletion in the AP3B1 gene causing Hermansky-Pudlak syndrome, type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22461475" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Exome sequencing reveals a pallidin mutation in a Hermansky-Pudlak-like primary immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26744459" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Mutations in AP3D1 associated with immunodeficiency and seizures define a new type of Hermansky-Pudlak syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16490934" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Pulmonary fibrosis in hermansky-pudlak syndrome. a case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19828536" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Case records of the Massachusetts General Hospital. Case 32-2009. A 27-year-old man with progressive dyspnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17195838" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A novel human primary immunodeficiency syndrome caused by deficiency of the endosomal adaptor protein p14.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10466444" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Chédiak-Higashi-Steinbrinck syndrome (CHS) in a 27-year-old woman--effects of G-CSF treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17293882" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Hematopoietic cell transplantation for Chediak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7756666" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Treatment of Chediak-Higashi syndrome by allogenic bone marrow transplantation: report of 10 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19252534" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Patients with early relapse of primary hemophagocytic syndromes or with persistent CNS involvement may benefit from immediate hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23804531" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Clinical characteristics and outcomes of chédiak-Higashi syndrome: a nationwide survey of Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25609327" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Successful stem cell transplantation in Chediak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8701696" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The role of high dose methylprednisolone and splenectomy in the accelerated phase of Chédiak-Higashi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17637689" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : In patients with Chediak-Higashi syndrome undergoing allogeneic SCT, does adding etoposide to the conditioning regimen improve the outcome?</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
